Journal article · 2018 · Open access
Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania
Malaria Journal, 17(1), 369 · Published 17 October 2018 · DOI 10.1186/s12936-018-2524-x
In brief
“Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania” is a 2018 journal article by Mwaka A. Kakolwa and 15 co-authors, published in Malaria Journal. OpenAlex counts 96 citations as of 19 November 2026, which puts it in the top 3% of works published in 2018 by citations. It is open access under a CC BY licence: the full text is free to read at Malaria Journal.
- Citations
- 96
- Most cited in
- 2020 (19)
- Field-weighted impact
- 9.94
- References
- 33
- Authors
- 16
Abstract
BACKGROUND: Artemisinin-based combination therapy (ACT) is the first-line anti-malarial treatment of uncomplicated malaria in most malaria endemic countries, including Tanzania. Unfortunately, there have been reports of artemisinin resistance and ACT failure from South East Asia highlighting the need to monitor therapeutic efficacy of ACT in these countries as recommended by World Health Organization. METHODS: Open-label single arm studies in mainland Tanzania were conducted in nine sentinel sites in 2011, 2012 and 2015 to assess the efficacy and safety of artemether/lumefantrine (AL) and artesunate/amodiaquine (ASAQ) using 28 days follow-up and dihydroartemisinin/piperaquine (DHAPQ) using 42 days follow-up. Mutations in the propeller domain of the Plasmodium falciparum kelch 13 (k13) gene and amplification of the P. falciparum plasmepsin 2 (pm2) gene, associated with artemisinin and piperaquine (PQ) resistance, were also investigated. RESULTS: Of the 428 patients enrolled, 328 patients provided study endpoint. For AL, the PCR corrected per-protocol analysis showed adequate clinical and parasitological response (ACPR) of 90.3% (n = 28; 95% CI 74.2-98.0) in Kyela 2012, 95.7% (n = 22; 95% CI 78.1-99.0) in Chamwino, 100% in Muheza (n = 29; 95% CI 88.1-100), 100% in Nagaga (n = 39; 95% CI 91.0-100) and Kyela 2015 (n = 60; 95% CI 94.0-100). For ASAQ, PCR corrected ACPR of 98% (n = 49; 95% CI 89.4-99.9) and 100% (n = 25; 95% CI 86.3-100) were observed in 2011 in Ujiji and Kibaha, respectively. For DHAPQ, the ACPR was 100% (n = 71; 95% CI 94.9-100). Of the 235 samples with genetic interpretable results, only 7 (3%) had non-synonymous k13 mutations. None of these are candidate or validated markers of artemisinin resistance and all patients carrying these alleles cleared the parasites on day 3. Of the DHAPQ group, 10% (3/29) of the samples with interpretable results had pm2 multiple copies and none of them was associated with treatment failure. CONCLUSION: All the tested ACT in mainland Tanzania were highly efficacious and none of validated k13 mutants associated with artemisinin resistance was observed. However, three isolates with multiple copy numbers of pm2 gene associated with PQ resistance among the limited samples tested successfully calls for further investigation. Trial registration Number ACTRN12615000159550. Registered 18th February 2015, https://www.anzctr.org.au/trial/MyTrial.aspx.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Kakolwa, M. A., Mahende, M. K., Ishengoma, D. S., Mandara, C. I., Ngasala, B., Kamugisha, E., Kataraihya, J. B., Mandike, R., Mkude, S., Chacky, F., Njau, R., Premji, Z., Lemnge, M. M., Warsame, M., Ménard, D., & Kabanywanyi, A. M. (2018). Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania. Malaria Journal, 17(1), 369. https://doi.org/10.1186/s12936-018-2524-x
MLA 9
Kakolwa, Mwaka A., et al. “Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania.” Malaria Journal, vol. 17, no. 1, 2018, p. 369. https://doi.org/10.1186/s12936-018-2524-x.
Chicago
Kakolwa, Mwaka A., Muhidin Kassim Mahende, Deus S. Ishengoma, Celine I. Mandara, Billy Ngasala, Erasmus Kamugisha, Johannes B. Kataraihya, et al. 2018. “Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania.” Malaria Journal 17 (1): 369. https://doi.org/10.1186/s12936-018-2524-x.
Harvard
Kakolwa, M. A. et al. (2018) ‘Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania’, Malaria Journal, 17(1), p. 369. doi:10.1186/s12936-018-2524-x.
IEEE
M. A. Kakolwa et al., “Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania,” Malaria Journal, vol. 17, no. 1, p. 369, 2018, doi: 10.1186/s12936-018-2524-x.
BibTeX
@article{kakolwa2018efficacy,
title = {{Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania}},
author = {Kakolwa, Mwaka A. and Mahende, Muhidin Kassim and Ishengoma, Deus S. and Mandara, Celine I. and Ngasala, Billy and Kamugisha, Erasmus and Kataraihya, Johannes B. and Mandike, Renata and Mkude, Sigsbert and Chacky, Frank and Njau, Ritha and Premji, Zul and Lemnge, Martha M. and Warsame, Marian and Ménard, Didier and Kabanywanyi, Abdunoor M.},
journal = {Malaria Journal},
year = {2018},
volume = {17},
number = {1},
pages = {369},
doi = {10.1186/s12936-018-2524-x},
url = {https://doi.org/10.1186/s12936-018-2524-x}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2019 | 18 | |
| 2020 | 19 | |
| 2021 | 10 | |
| 2022 | 10 | |
| 2023 | 6 | |
| 2024 | 18 | |
| 2025 | 7 | |
| 2026 | 8 |
Its field-weighted citation impact is 9.94: it has been cited 9.94 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- artemisinin-based combination therapy
- artemisinin resistance
- piperaquine resistance
- artemether-lumefantrine
- artesunate-amodiaquine
- dihydroartemisinin-piperaquine
- Plasmodium falciparum
- treatment efficacy
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Kakolwa, M. A., Mahende, M. K., Ishengoma, D. S., Mandara, C. I., Ngasala, B., Kamugisha, E., Kataraihya, J. B., Mandike, R., Mkude, S., Chacky, F., Njau, R., Premji, Z., Lemnge, M. M., Warsame, M., Ménard, D., & Kabanywanyi, A. M. (2018). Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania. Malaria Journal, 17(1), 369. https://doi.org/10.1186/s12936-018-2524-x
How many times has this paper been cited?
96 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Malaria Journal: sign in and open the PDF from this page.
Who wrote this paper?
Mwaka A. Kakolwa, Muhidin Kassim Mahende, Deus S. Ishengoma, Celine I. Mandara, Billy Ngasala, Erasmus Kamugisha, Johannes B. Kataraihya, Renata Mandike, Sigsbert Mkude, Frank Chacky, Ritha Njau, Zul Premji and 4 more.
What is the DOI of this paper?
10.1186/s12936-018-2524-x, permanently at https://doi.org/10.1186/s12936-018-2524-x. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.